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INTRODUCTION
Chronic kidney disease (CKD) is a key determinant of poor health outcomes in major non-communicable diseases such as cardiovascular (CV) disease and diabetes, and it is increasingly recognized as a global public health problem [1, 2] . The burden of CKD includes not only progression to end-stage renal disease (ESRD), but also complications related to renal impairment and increased risk of CV disease [2] . The increased morbidity and mortality related to CKD may be reduced with early detection and effective management to prevent or delay further progression of renal dysfunction and its associated complications [1, 2] .
Interest in the relationship between serum uric acid (SUA) and CKD has been renewed recently, due in part to new experimental and clinical data [3, 4] . The debate continues regarding whether SUA plays a causal role in CKD or is simply a marker of renal dysfunction [3] . Emerging evidence continues to support a pathogenic role for SUA in CKD [5] [6] [7] [8] [9] . Notably, this renewed interest has coincided with the development of sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus (T2DM); these agents, acting via the kidneys in an insulin-independent manner, reduce SUA and potentially improve renal outcomes [10] [11] [12] [13] . In this review, we will discuss the currently available evidence on the relationship between SUA and CKD, and how the uric acid-lowering effects of SGLT2 inhibitors may contribute to renoprotection. This article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by the author.
URIC ACID AND HYPERURICEMIA
Uric acid is a weak organic acid that under physiologic conditions exists mainly as monosodium urate [14] ; therefore, uric acid and urate, although chemically different, are generally interchangeable terms. In higher primates, uric acid is the end product of the metabolism of unwanted purine nucleotides [4, 10, 15] . Unlike other mammals, higher primates lack the enzyme uricase that converts uric acid to allantoin [15] [16] [17] . Beneficial effects of uric acid, such as its ability to scavenge harmful radicals, may have been evolutionarily advantageous [15, 16] . However, increased SUA levels can lead to urate crystallization and associated complications, such as kidney stones and gout. There is also increasing evidence that increased SUA levels may negatively affect CV and renal health in a crystal-independent manner [18] .
About two-thirds of uric acid is produced endogenously, primarily in the liver, muscle, and intestine, and one-third is derived from dietary sources, including fructose, alcohol, and purine-rich foods like certain meats and seafood [4] . Uric acid is produced from fructose via an endogenous pathway as well as from dietary sources (e.g., corn syrup), and a high fructose intake can cause intracellular adenosine triphosphate depletion and nucleotide turnover, with uric acid formation [19] . In diabetes, fructose is generated endogenously via the polyol pathway; blocking the metabolism of fructose in a diabetic mouse model has been found to mitigate the development of tubulointerstitial injury through blocking the production of tubular uric acid [20] .
Overall, the SUA level is determined primarily by a balance of uric acid generation, reabsorption, and excretion in the kidney, but it can also be influenced by other factors, like dietary purine intake, hydration status, and use of diuretics [4, 15] . Volume depletion will reduce uric acid excretion independently of urine flow [21] , while a comparison of mannitol-and glucose-associated osmotic diuresis showed that, for each osmolar unit, glucosuric diuresis had a threefold greater uricosuric effect [22] .
Uric acid is excreted primarily via the kidneys; therefore, the kidneys play an important role in regulating SUA levels [4, 23] .
In the kidneys, urate reabsorption and secretion are regulated by multiple urate transporters. For example, urate transporter 1 (URAT1) is expressed in the apical membrane of proximal tubule cells and is responsible for urate reabsorption [15, 24] . In addition, two isoforms of the urate transporter SLC2A9 (glucose transporter 9 [GLUT9]) are known, one expressed at the baso-lateral side of the proximal tubule and the other on the apical membranes in the collecting duct. Normally, no glucose will reach the collecting ducts, but in diabetes (and especially with SGLT2 inhibition) large amounts of glucose can be excreted: GLUT9 is now exchanging glucose and fructose for uric acid, and therefore plays an important role in regulating urate homeostasis [23, [25] [26] [27] [28] [29] . Only a small fraction of uric acid (8-10%) is excreted (net urinary urate excretion is 250-750 mg/day), as about 90% of filtered urate is reabsorbed [4] . Obesity, insulin resistance, hypertension, and diuretic use have The definition of hyperuricemia in adults is not universally agreed upon, but commonly used thresholds are in the range of 6-7 mg/dL (350-400 lM/L), and are usually higher for men than for women [23] . The presence of hyperuricemia has been associated with a number of disorders including CV and renal disease, metabolic syndrome, diabetes, and hypertension [30] . In patients with T2DM, hyperuricemia is associated with an increased risk of developing gout, kidney stones, vascular complications [31, 32] , and death [32] .
Establishing the exact relationship between SUA level and diabetes has been complicated by the fact that both hypouricemia and hyperuricemia have been linked to diabetes [33] . SUA levels may be low in patients with recently diagnosed diabetes due to increased urate excretion [34] . Hyperuricemia, on the other hand, has been associated with the development of diabetes, especially in the context of insulin resistance and impaired glucose tolerance [35] .
In a large population-based study, increased SUA levels were shown to be an independent risk factor for developing T2DM, and one-quarter of diabetes cases could be attributed to high SUA levels [36] . These findings may have a strong public health impact, as lowering SUA may decrease the incidence of diabetes, if the relationship is causal [37] .
CHRONIC KIDNEY DISEASE
CKD is defined as abnormalities of kidney structure or function that persist for more than 3 months with health implications [37, 38] .
Abnormalities include decreased glomerular filtration rate (GFR; \60 mL/min/ ] is 22.0% [40] . Diabetic kidney disease is the single strongest predictor of mortality in patients with diabetes [41, 42] . Furthermore, CKD is associated with an eight-to tenfold increase in CV mortality, and its presence is a negative risk factor in patients with diabetes and hypertension [1] . In developed countries like the USA, diabetic kidney disease is the leading cause of ESRD [41] . [49] . The suggestion that hyperuricemia is a risk factor for CKD is supported by many studies. Preclinical data suggest that hyperuricemia induces renal injury through multiple crystal-independent mechanisms involving renal vasoconstriction mediated by endothelial dysfunction, inflammation, and activation of the renin-angiotensin system (Fig. 1) [8, 17, 18, [50] [51] [52] [53] . Hyperuricemia has also been associated with afferent renal arteriolopathy, tubulointerstitial fibrosis, and renal inflammation [54] . Data from most epidemiological studies suggest that uric acid is a major independent risk factor for the development and progression of renal disease in patients both with [9, [55] [56] [57] and without diabetes [56, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] . In a recent meta-analysis of 13 observational trials involving over 190,000 patients [56] , the presence of hyperuricemia was an independent predictor of new-onset CKD development. The effect was seen in subsets of patients with and without diabetes, and the magnitude of the effect was comparable in both subsets. Possibly reflecting dietary differences, this effect was more pronounced in Western populations than in Asian populations [56] . Notably, in patients with increased SUA levels, the risk of developing new-onset CKD increased as the duration of follow-up increased, suggesting that hyperuricemia may play a role in the long-term progression of chronic renal dysfunction [56] . In a recent cross-sectional study enrolling 3212 Chinese patients with T2DM, the prevalence of diabetic kidney disease was significantly elevated in hyperuricemia subjects and increased with increasing uric acid levels [55] . The presence of a mutation in the urate transporter GLUT9 strongly predicted progression of CKD in a cohort of 755 patients with CKD [69] . Lastly, in a study of 4233 women, increased SUA during pregnancy was associated with a higher risk of subsequent hospitalization for significant atherosclerotic-related events, including renal failure, diabetic ketoacidosis, hypertensive crisis, and CV events [70] .
Some epidemiological studies, however, have reported no significant relationship between hyperuricemia and progression of kidney disease and development of kidney failure [71, 72] . In a prospective analysis of the Mild to Moderate Kidney Disease study, 177 patients with non-diabetic primary CKD and various stages of renal impairment were Fig. 1 Potential mechanisms of uric acid-induced kidney disease [4] . COX-2 Cyclooxygenase-2, ECM extracellular matrix, EMT epithelial-to-mesenchymal transition, NO nitric oxide, RAS renin-angiotensin system, VEC vascular endothelial cells, VSMC vascular smooth muscle cells.
Reprinted from Seminars in Nephrology, Vol. 32, Issue 5. Kang DH, Chen W, Uric acid and chronic kidney disease: new understanding of an old problem. pp. 447-52. Copyright 2011, with permission from Elsevier followed for 7 years [71] . Increased SUA levels predicted CKD progression only when patients receiving uric acid-lowering drugs were excluded from the analysis. After adjusting for baseline GFR and proteinuria, hyperuricemia was no longer an independent predictor of CKD progression [71] . Similarly, in the Modification of Diet in Renal Disease study, 838 patients with stage 3-4 CKD were followed for median of 10 years [72] . In continuous analyses, each 1 mg/dL increase in SUA level was associated with an increased risk of all-cause mortality and CV disease-related mortality, but not with progression to kidney failure [72] .
Diabetes
In patients with diabetes, a multifactorial show that such interventions can slow down the progression of CKD [50, 73] . In patients with type 1 diabetes mellitus, elevated SUA levels at baseline were shown to predict the development of CKD in several trials [5] [6] [7] 57] .
A recent multiple regression analysis performed on 1108 patients with type 1 diabetes identified SUA as the third most important risk factor after tumor necrosis factor receptor 1 and albuminuria, associated with early progressive renal decline [74] . Similar results have been reported in patients with T2DM. For example, in a study of 1449 patients with T2DM, normal kidney function, and no proteinuria, subjects were followed for 5 years to assess the occurrence of new-onset CKD [9] . During the 5-year period, the cumulative incidence of CKD was significantly higher in patients with baseline hyperuricemia ([7.0 mg/dL) compared with those without hyperuricemia (29.5% vs. 11.4%). A multivariate analysis in this population of patients with T2DM
confirmed that hyperuricemia, together with older age, use of antihypertensive drugs, and lower eGFR and higher albuminuria at baseline, was an independent risk factor for the development of CKD [9] .
IgA Nephropathy
IgA nephropathy (IgAN) is the most common type of primary glomerular disease characterized by variable tubulointerstitial lesions, and it can progress to ESRD over time [75] . In patients with IgAN, SUA levels have been shown to correlate with renal damage [76, 77] and progression of IgAN [58, 78, 79] . In a recent study of 93 patients with IgAN, baseline SUA levels significantly predicted the change in eGFR over a 6-month period after adjusting for multiple factors, including baseline GFR and albumin level [58] . In a long-term study (mean follow-up 5 years) of 348 consecutive cases of IgAN, patients with high SUA levels at baseline were significantly more likely to experience a decline in GFR (41% vs. 16%) and develop ESRD (65% vs. 35%) compared with patients with SUA levels within the normal range [78] .
Acute Kidney Injury
Lastly, little is known about the relationship between SUA and acute kidney injury (AKI).
Data from Atherosclerosis Risk in Communities, a population-based study of over 11,000 participants followed for an average of 12 years, indicated that increased plasma urate ([5.0 mg/dL) was independently associated with the risk of hospitalization for AKI [80] 
Allopurinol
Several small studies have explored the impact of treatment with the xanthine oxidase inhibitor allopurinol on renal outcomes [81] [82] [83] [84] [85] . Recent meta-analyses have produced variable results. In an analysis of randomized trials of patients with or without CKD at baseline, uric acid-lowering therapy with allopurinol had no effect on GFR compared with controls in five trials (n = 346) but abrogated increases in serum creatinine in three trials (n = 130) [85, 86] . 
Febuxostat and Topiroxostat
Febuxostat is a non-purine selective inhibitor of xanthine oxidase approved by the US FDA for the treatment of adult hyperuricemia with gout (not for hyperuricemia alone), and can be used evidence that strategies to reduce SUA levels may reduce renal risk.
SGLT2 Inhibitors
The urate transporter via induction of glycosuria: higher levels of glucose in the urine due to SGLT2 inhibition result in a higher level of exchange of uric acid across the apical membrane of tubular cells, so more uric acid is released from blood into the urine, ultimately reducing SUA levels [10, 102, 103] . In a pooled analysis of data from four phase 3 trials, canagliflozin was shown to reduce SUA levels compared with placebo [10] . In a subgroup with hyperuricemia at baseline, 20-30% of patients with hyperuricemia achieved normal SUA levels after 26 weeks of treatment with canagliflozin [10] . Similarly, in a meta-analysis of small, 
